Amgen announced positive results from a 24-week study of its experimental obesity drug, MariTide. Participants with type 2 ...
Amgen's experimental obesity drug MariTide shows promise in helping maintain weight loss, ahead of results from a mid-stage ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback